The report: “Topical Pain Relief Market Forecast (2020-2025)”, by IndustryARC, covers an in-depth analysis of the following segments of the Topical Pain Relief Market. 

By Type: Prescription Pain Relief, Over-The-Counter Pain Relief

By Therapeutic Class: Non-Opioids, Nonsteroidal Anti-Inflammatory Drug, Methyl Salicylate, Capsaicin, Lidocaine, Opioids, Buprenorphine and Fentanyl

By Formulation: Cream, Gel, Spray, and Patch

By Distribution Channel: Pharmacy Drug Store, E-Commerce, Others

By Geography: North America, Europe, Asia Pacific and Rest of the World (RoW)

The non-Opioids segment held the largest share in the Topical Pain Relief in 2019 and is estimated to grow at a CAGR of 5.41% during the forecast period 2020-2025.This is owing to the high preferability and availability of non-opioids drugs. Nonopioids are further segmented into   Nonsteroidal Anti-Inflammatory Drug,   Methyl Salicylate,   Capsaicin, and Lidocaine. Lidocaine is a local anesthetic that works by causing temporary numbness or loss of feeling in the skin and mucous membranes. Topical non-steroidal anti-inflammatory drugs provide good levels of pain relief in acute conditions such as sprains, strains, and overuse injuries, probably similar to that provided by oral nonsteroidal anti-inflammatory drugs. The tricyclic antidepressants most commonly used in the treatment of neuropathic pain are amitriptyline, imipramine, nortriptyline, and desipramine, as they all are potent norepinephrine reuptake inhibitors. Capsaicin topical is used for temporary relief of muscle or joint pain caused by strains, sprains, arthritis, bruising, or backaches. Capsaicin topical is also used to treat nerve pain (neuralgia) in people who have had herpes zoster or shingles. Cannabinoid receptors and endocannabinoids are present in pain circuits from the peripheral sensory nerve endings up to the brain. Cannabinoid receptor agonists modulate nociceptive thresholds by regulating neuronal activity, but they also relieve pain by acting on non-nervous tissues. The Non-Opioids is set to be the highest growing segment and is estimated to register highest CAGR during the forecast period 2020-2025.

E-Commerce segment held the largest share in the Topical Pain Relief in 2019 owing to the significant increase in digital literacy among the global population. Large population and surge in awareness about topical pain relievers among patients, rise in prevalence of diseases associated with chronic pain among the population, high awareness about the side effects caused by systemic administration of drugs and increase in the number of people suffering from migraine and schizophrenia are boosting the growth of the topical pain relief market. E-Commerce is set to be the highest growing segment and is estimated to register the highest CAGR during the forecast period 2020-2025.

North America dominated the topical pain relief market in 2019 with a share of more than 37.6% followed by the Asia Pacific. This is owing to the high population base, increase in disposable income, and improvement in patient awareness about topical pain relief products. High awareness about the side effects caused by systemic administration of drugs and an increase in the number of people suffering from migraine & schizophrenia along with the awareness and improvement in access of healthcare medication & education is set to increase the growth of the topical pain relief market in the North America region.

However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the rise in prevalence of chronic diseases including cancer, arthritis, and diabetes among others coupled with the increase in investments by various multinational companies. An increase in the old age group population and unhealthy food habits with the rise in awareness among patients about the adverse effects of particular drugs and associated pathways, increase in the number of patients undergoing prolonged treatment for diseases such as skin cancer is set to increase the growth of the topical pain relief market in the Asia Pacific region.

An increase in the prevalence of arthritis and other bone-related conditions is increasing the growth of the topical pain relief market owing to the development of an online platform for the topical therapeutics and high potential in untapped markets in the emerging economies.  The rise in prevalence of chronic diseases including cancer, arthritis, diabetes, growing demand in sports and athletic player, growing awareness of online pharmacy and others along with an increase in investments by various multinational companies and high demand for topical pain relievers among athletes and lesser side effects as compared to conventional oral medicines. Thus, increasing the growth of the topical pain relief market during the forecast period 2020-2025.

Increase in geriatric population and the increase in the adoption of topical pain relief by sports players are increasing the growth of the topical pain relief market owing to the rise in adoption of topical pain relief products as they cause lesser side effects as compared to oral pain relief, upsurge in geriatric population across the world, increase in disposable income, and improvement in patient awareness about topical pain relief products and increase in demand for topical pain relief by sports players. Thus, increasing the growth of the topical pain relief market during the forecast period 2020-2025.

Some of the factors which can impede the growth of the topical pain relief market are it causes irritated skin and they have a strong odor or unpleasant smell.

Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the topical pain relief market. In 2019, Topical Pain Relief Market share is consolidated by the top ten players present in the market. Topical Pain Relief, top 10 companies are Advacare Pharma, Glaxosmithkline Plc, Johnson Johnson, Nestl S A, Pfizer Inc., Reckitt Benckiser Group Plc, Sanofi, Sun Pharmaceutical Industry Ltd and Topical Biomedics Inc among others.